Literature DB >> 33168500

[Silencing of SLP-2 inhibits the migration and invasion of cervical cancer cells in vitro].

Jialu Zhang1, Guolin Hu2, Lei Liu1, Huodi Chen1, Danjuan Li1, Weijiang Liang1.   

Abstract

OBJECTIVE: To investigate the effect of SLP-2 silencing on the migration and invasion of human cervical cancer cells and explore the mechanism.
METHODS: Small interfering RNA (siRNA) was used to knockdown the expression of SLP-2 in Hela cells and Siha cells. At 48 h after the transfection, the cells were examined for SLP-2 expression with Western blotting, and wound healing assay and Transwell assay were used to evaluate the changes in the cell migration; Matrigel Transwell assay was used to evaluate the changes in the invasion ability of the cells. The expressions of E-cadherin, β-catenin, vimentin and Twist in Hela and Siha cells following the transfection were detected with Western blotting.
RESULTS: Compared with the control cells, siRNA transfection significantly lowered the expression of SLP-2 and suppressed the migration and invasion ability of Hela cells and Siha cells (P < 0.01). Silencing SLP-2 induced obvious up-regulation of epithelial cell phenotype proteins E-cadherin and β-catenin, down- regulated the expression of interstitial cell phenotype protein vimentin, and lowered the expression of Twist in the cells.
CONCLUSIONS: Silencing SLP-2 via siRNA transfection can inhibit epithelial-mesenchymal transition of human cervical cancer cells and lower their migration and invasion abilities possibly in relation with downregulated expression of Twist.

Entities:  

Keywords:  SLP-2; cervical cancer; epithelial-mesenchymal transition; invasion; migration

Year:  2018        PMID: 33168500      PMCID: PMC6765530          DOI: 10.3969/j.issn.1673-4254.2018.07.07

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  31 in total

Review 1.  Focus on central nervous system neoplasia.

Authors:  David N Louis; Scott L Pomeroy; J Gregory Cairncross
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

2.  Correlation of TWIST2 up-regulation and epithelial-mesenchymal transition during tumorigenesis and progression of cervical carcinoma.

Authors:  Yan Li; Wei Wang; Wenwen Wang; Runfeng Yang; Tian Wang; Tiefen Su; Danhui Weng; Tao Tao; Wei Li; Ding Ma; Shixuan Wang
Journal:  Gynecol Oncol       Date:  2011-10-22       Impact factor: 5.482

Review 3.  Matrix metalloproteinases and tumor metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

Review 4.  Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer.

Authors:  Patricia J Eifel
Journal:  Nat Clin Pract Oncol       Date:  2006-05

5.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

Review 6.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

Review 7.  EMT in developmental morphogenesis.

Authors:  Yukiko Nakaya; Guojun Sheng
Journal:  Cancer Lett       Date:  2013-02-24       Impact factor: 8.679

8.  Cyr61 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway.

Authors:  Chun-Han Hou; Feng-Ling Lin; Sheng-Mon Hou; Ju-Fang Liu
Journal:  Mol Cancer       Date:  2014-10-19       Impact factor: 27.401

9.  Stomatin-like protein 2 is overexpressed in cervical cancer and involved in tumor cell apoptosis.

Authors:  Huan Deng; Yongjian Deng; Feiye Liu; Jie Chen; Zheng Li; Kelei Zhao; Xiaoqian Guan; Weijiang Liang
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

Review 10.  Modes of invasion during tumour dissemination.

Authors:  Pahini Pandya; Jose L Orgaz; Victoria Sanz-Moreno
Journal:  Mol Oncol       Date:  2016-12-09       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.